Quince Therapeutics, Inc. Logo

Quince Therapeutics, Inc.

Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.

QNCX | US

Overview

Corporate Details

ISIN(s):
US22053A1079
LEI:
Country:
United States of America
Address:
611 GATEWAY BLVD., SUITE 273, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing and commercializing therapeutics for rare diseases. The company's core technology is its proprietary Autologous Intracellular Drug Encapsulation (AIDE) platform, a novel drug/device combination that encapsulates drugs within a patient's own red blood cells. This delivery system is designed to improve tolerability, enhance tissue biodistribution, and reduce the adverse effects of potent medicines. Quince's lead product candidate, eDSP, is in a pivotal Phase 3 clinical trial for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved therapies. The eDSP System has received Fast Track designation from the U.S. Food and Drug Administration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Quince Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quince Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quince Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America ENTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.